CervoMed
Open
$3.74
Prev. Close
$3.74
High
$3.75
Low
$3.74
Market Snapshot
$33.77M
-1.3
-2.03
$9.74M
15
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
emptyResult
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Recently from Cashu
CervoMed Stock Update: Key Developments and Insights.
Please provide the text you would like me to summarize, and I'll be happy to help!
CervoMed Stock Update: Key Developments and Insights
Please provide the content you would like me to summarize, and I'll be happy to help!
CervoMed Unveils Innovative Therapeutic Approach for Neurodegenerative Disease Treatment
CervoMed Advances Neurodegenerative Disease Research with New Therapeutic Approach CervoMed, a biotechnology firm specializing in innovative treatments for neurodegenerative diseases, unveils a promis…
Please provide the content you would like me to summarize, and I'll create a title for you.
Sure! Please provide the text you would like me to summarize.